Mattheus Cornelis De Wilde,Robert Johan Joseph Hageman
申请号：
US16739663
公开号：
US20200261488A1
申请日:
2020.01.10
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The invention pertains to a composition for use in producing white matter, producing myelin and/or reducing brain lesion size in a mammal suffering from or recovering from traumatic brain injury, comprising enterally administering to the subject a composition comprising therapeutically effective amounts of: (i) one or more of uridine, cytidine, or salts, phosphates, acyl derivatives or esters thereof； (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6； DHA), eicosapentaenoic acid (20:5； EPA) and docosapentaenoic acid (22:5； DPA), preferably at least DHA, more preferably DHA and EPA, wherein the lipid fraction comprises less than 2 weight % of α-linolenic acid (ALA), calculated on the weight of all fatty acids； (iii) choline, or salts or esters thereof； and (iv) at least one vitamin B selected from vitamins B6, B9 and B12.
